Denali Therapeutics Inc (DNLI) Stock Analysis

Denali Therapeutics Inc (DNLI) is a publicly traded company in the HEALTHCARE sector. It trades at $19.35, carries a market capitalization of $3.24B. This page summarizes the public market data, fundamentals, and frequently asked questions for DNLI, with GNG Research's proprietary safety, quality, and valuation analysis available to members.

Sector: HEALTHCARE - BIOTECHNOLOGY

Exchange: NASDAQ

Key Metrics

Market Sentiment

Denali Therapeutics Inc currently has a Neutral sentiment score of 0.06.

About Denali Therapeutics Inc

Denali Therapeutics Inc. is a prominent biopharmaceutical firm dedicated to developing innovative treatments for neurodegenerative diseases, targeting significant unmet medical needs within this critical healthcare sector. Based in South San Francisco, California, the company employs its proprietary technology platforms to craft disease-modifying therapies that address the underlying biological mechanisms of various neurological disorders. Denali’s robust pipeline includes a range of promisin...

GNG Research Analysis

GNG Research scores Denali Therapeutics Inc (DNLI) on three proprietary dimensions — a Safety score, a Quality score, and a Valuation score — alongside fair value estimates and buy-price targets for 5,000+ companies. These ratings are reserved for members. Read how the scores are calculated on our methodology page, or see GNG Research plans to unlock the full rating for DNLI.

Frequently Asked Questions

Does DNLI pay dividends?

Denali Therapeutics Inc (DNLI) does not currently pay a regular dividend.

What is DNLI's market cap?

Denali Therapeutics Inc (DNLI) has a market capitalization of $3.24B with a current stock price of $19.35.